Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
March 2026
in “
American Journal of Clinical Dermatology
”
Research cited in this study
23 / 23 resultsresearch Real-World Assessment of Ritlecitinib in Patients with Severe Alopecia Areata: A 24-Week Multicentre Retrospective Study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Alopecia Areata: Pathogenesis, Diagnosis, And Therapies
Alopecia areata causes unpredictable hair loss, and more research is needed to fully understand and treat it effectively.
research Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The Allegro Phase 2b/3 Randomized Clinical Trial
Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
research Efficacy and Safety of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, in Adolescent and Adult Patients with Alopecia Totalis and Alopecia Universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research Real-Life Effectiveness and Safety of Baricitinib in Patients with Severe Alopecia Areata: A 24-Week Italian Study
Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.
research Assessment of Clinician-Reported Outcome Measures for Alopecia Areata: A Systematic Scoping Review
A comprehensive scoring system for alopecia areata severity is needed.
research Italian National Registry of Alopecia Areata: An Epidemiological Study of 699 Italian Patients
Alopecia areata is hard to manage and affects quality of life.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
research Janus Kinase Inhibitors for Alopecia Areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial
Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
research Scalp Hair Regrowth Is Associated With Improvements in Health-Related Quality of Life and Psychological Symptoms in Patients With Severe Alopecia Areata: Results From Two Randomized Controlled Trials
Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors
New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.
research Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
research Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management
JAK inhibitors show promise for treating alopecia areata, but more research is needed.
research A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results
Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
research Common Causes of Hair Loss: Clinical Manifestations, Trichoscopy, and Therapy
The document concludes that understanding and treating hair loss requires recognizing its various types and using appropriate diagnostic tools and treatments.
research Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata
New tools help assess eyebrow, eyelash, and nail changes in Alopecia Areata, improving understanding of patient experiences.
research Italian Guidelines in Diagnosis and Treatment of Alopecia Areata
The Italian guidelines offer advice for diagnosing and treating alopecia areata based on expert opinion and limited clinical trial evidence.
research Investigative Guidelines for Alopecia Areata
Guidelines help design better trials to compare alopecia areata treatments.